Lannett — Q2 FY2019 Earnings Presentation
9 slides from Lannett's earnings presentation, Feb 7, 2019
Slide 1: Recent Product Launches – Competitive Profile
RECENT PRODUCT LAUNCHES – COMPETITIVE PROFILE New Products launched January 2018 through December 2018: Buprenorphine and Naloxone SL Tablets | Clarithromycin ER Tablets | Dexmethylphenidate ER Caps | Diclofenac Sodium ER Tablets | Diphenoxylate Atropine Sulfate IR Tablets | Dronabinol IR Capsules |
Slide 2: Planned ANDA Launches by Quarter in Calendar 2019
PLANNED ANDA LAUNCHES BY QUARTER IN CALENDAR 2019 (MAT Dec ‘18) Excludes pending NDA for Numbrino. Information on this slide is forward looking. Please refer to our included forward looking statements disclosure. The statements on this slide are inherently uncertain and actual results could differ m
Slide 3: Product Launches – Projected Net Sales
PRODUCT LAUNCHES – PROJECTED NET SALES $ in millions Products Already Launched Calendar Year 2018 Planned Product Launches Calendar Year 2019 • Methylphenidate ER ~ $10 ~10 launches Pipeline: Total of 60 products in various stages of development through launch readiness Fiscal 2019 Full-Year Estimat
Slide 4: Cost Reduction Plan
COST REDUCTION PLAN CURRENT FORECAST Philadelphia manufacturing facility: closed, production transferred to Seymour Specialty sales force: eliminated 1Cost savings based on FY-18 run-rate. 2Investments for additional ANDA development and increased capacity. 5 Information on this slide is forward loo
Slide 5: Filling the Levothyroxine Projected Profit Gap
FILLING THE LEVOTHYROXINE PROJECTED PROFIT GAP Annual Levo Gross Profit, Normalized = $100 Million $ in millions Products Already Launched Calendar Year 2018 Planned Product Launches Calendar Year 2019 Cost Reduction Plan Through FY20, Net Savings ~ $3 Fiscal 2019 Full-Year Estimate Fiscal 2020 Full
Slide 6: Update
INSULIN GLARGINE UPDATE Information on this slide is forward looking. Please refer to our included forward looking statements disclosure. The statements on this slide are inherently uncertain and actual results could differ materially from the statements made herein.
Slide 7: Status Update: Glargine Biosimilarity
INSULIN GLARGINE STATUS UPDATE Glargine biosiimilarity to Chinese Lantus demonstrate biosimilarity to US Lantus to recently completed and results show conducted against US Lantus Trial Application filed for first clinical trial *Sprague Dawley Rat Study, 58 animal study conducted by Covance China **
Slide 8: Status Update: HEC Glargine Similar to US and Chinese Lantus
INSULIN GLARGINE STATUS UPDATE HEC Glargine similar to US and Chinese Lantus – Animal Study* Table: Comparisons of Insulin Glargine HEC, US-Lantus and CN-Lantus in PD Endpoint /US Lantus HEC /CN-Lantus Lantus 9 *Sprague Dawley Rat Study, 58 animal study conducted by Covance China, Study results cann
Slide 9: Status Update: HEC Glargine Animal Study
INSULIN GLARGINE STATUS UPDATE Lannett HEC Glargine similar to US and Chinese Lantus - Animal Study* Pasma Gucose pita <P aos."P<oane"pc oot Greuptth, > GUA Yee 4a. 5 Dg oo ‘wc hOVA Dott tasting Sco og 0 Gea, 5 5 eg 8 i co oun rie HEC, Sg Sone, Ding Dy pet 7 ie fr Table: Comparisons of insulin Glarg